Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Proton pump inhibitors and durvalumab in PACIFIC. Local targets link to admitted publications; unresolved targets remain external evidence.
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
10.1016/s1470-2045(26)00191-9 · 2026 · External reference
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
10.1200/jco.21.01308 · 2022 · External reference
Lymphocyte nadir and recovery dynamics for locally advanced thoracic malignancies undergoing concurrent chemo-irradiation: establishment of organs-at-risk constraints
10.1016/j.radonc.2025.111009 · 2025 · External reference
Pretreatment risk model for radiation-induced lymphopenia is associated with adjuvant durvalumab efficacy in patients with unresectable stage III NSCLC
10.1016/j.ijrobp.2026.02.238 · 2026 · External reference
Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomized control trials
10.1016/j.jtho.2022.02.003 · 2022 · External reference
